Origanum Sipyleum Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells

References

• Sharifi-Rad M, Berkay Yılmaz Y, Antika G, Salehi B, Tumer TB, Kulandaisamy Venil C, Das G, Patra JK, Karazhan N, Akram M, et al. Phytochemical constituents, biological activities, and health-promoting effects of the genus Origanum. Phytother Res. 2021;35(1):95–121. doi:10.1002/ptr.6785
   PubMed Web of Science ®Google Scholar
• Ietswaart JH, Ietswaart J. A taxonomic revision of the genus Origanum (Labiatae). The Hague: Leiden University Press, 1980.
   Google Scholar
• Uysal B, Sozmen F, Kose EO, Gokhan Deniz I, Oksal BS. Solvent-free microwave extraction and hydrodistillation of essential oils from endemic Origanum husnucanbaseri H. Duman, Aytac & A. Duran: comparison of antibacterial activity and contents. Nat Prod Res. 2010;24(17):1654–63. doi:10.1080/14786419.2010.488632
   PubMed Web of Science ®Google Scholar
• Abbasi-Maleki S, Kadkhoda Z, Taghizad-Farid R. The antidepressant-like effects of Origanum majorana essential oil on mice through monoaminergic modulation using the forced swimming test. J Tradit Complement Med. 2020;10(4):327–35. doi:10.1016/j.jtcme.2019.01.003
   PubMedGoogle Scholar
• Baser K, Özek T, Kürkçüoglu M, Tümen G. Composition of the essential oil of Origanum sipyleum of Turkish origin. J Essential Oil Res. 1992;4(2):139–42. doi:10.1080/10412905.1992.9698035
   Google Scholar
• Durmuşkahya C, Alp H, Hortooğlu ZS, Toktas Ü, Kayalar H. X-ray fluorescence spectroscopic determination of heavy metals and trace elements in aerial parts of Origanum sipyleum L from Turkey. Trop J Pharm Res. 2016;15(5):1013–5. doi:10.4314/tjpr.v15i5.16
   Web of Science ®Google Scholar
• Kargıoğlu M, Cenkci S, Serteser A, Evliyaoğlu N, Konuk M, Kök MŞ, Bağcı Y. An ethnobotanical survey of inner-West Anatolia, Turkey. Hum Ecol. 2008;36(5):763–77. doi:10.1007/s10745-008-9198-x
   Web of Science ®Google Scholar
• Zengin G, Ferrante C, Orlando G, Zheleva-Dimitrova D, Gevrenova R, Recinella L, Chiavaroli A, Leone S, Brunetti L, Aumeeruddy MZ, et al. Chemical profiling and pharmaco-toxicological activity of Origanum sipyleum extracts: Exploring for novel sources for potential therapeutic agents. J Food Biochem. 2019;43(11):e13003. doi:10.1111/jfbc.13003
   PubMed Web of Science ®Google Scholar
• Ozbilgin A, Durmuskahya C, Kayalar H, Ertabaklar H, Gunduz C, Ural IO, Zeyrek F, Kurt O, Cavus I, Toz SO, et al. Antileishmanial activity of selected Turkish medicinal plants. Trop J Pharm Res. 2015;13(12):2047. doi:10.4314/tjpr.v13i12.15
   Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330–40. doi:10.1056/NEJM199904293401706
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72. doi:10.1056/NEJM199907153410306
   PubMed Web of Science ®Google Scholar
• Santos FP, Quintas-Cardama A. New drugs for chronic myelogenous leukemia. Curr Hematol Malig Rep. 2011;6(2):96–103. doi:10.1007/s11899-011-0079-9
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang W-S, Xu Q, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–12. doi:10.1016/j.ccr.2009.09.028
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE Trial. Blood. 2014;124(21):3135. doi:10.1182/blood.V124.21.3135.3135
   Web of Science ®Google Scholar
• Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, et al. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015;2(9):e376-83–e383. doi:10.1016/S2352-3026(15)00127-1
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428–42. doi:10.1016/j.ccr.2014.07.006
   PubMed Web of Science ®Google Scholar
• Trease GE, Evans WC. Trease and evans pharmacognosy: A physicians’s guide to herbal medicine. London: W.B. Saunders; 2002.
   Google Scholar
• Harborne JB. Phytochemical methods, A guide to modern techniques of plant analysis. Chapman and Hall, New York: Springer Science & business media; 1998.
   Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–6. doi:10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi:10.1016/0065-2571(84)90007-4
   PubMedGoogle Scholar
• Kayabasi C, Yelken BO, Asik A, Okcanoglu TB, Sogutlu F, Gasimli R, Susluer SY, Saydam G, Avci CB, Gunduz C, et al. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. Eur J Pharmacol. 2021;910:174446. doi:10.1016/j.ejphar.2021.174446
   PubMed Web of Science ®Google Scholar
• Yin SY, Wei WC, Jian FY, Yang NS. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med. 2013;2013:302426. doi:10.1155/2013/302426
   PubMed Web of Science ®Google Scholar
• Kayabasi C, Okcanoglu TB, Yelken BO, Asik A, Susluer SY, Avci CB, Saydam G, Gunduz C. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia. Gene. 2017;637:173–80. doi:10.1016/j.gene.2017.09.036
   PubMed Web of Science ®Google Scholar
• Karade PG, Jadhav NR. In vitro studies of the anticancer action of Tectaria cicutaria in human cancer cell lines: G0/G1 p53-associated cell cycle arrest-Part I. J Tradit Complement Med. 2018;8(4):459–64. doi:10.1016/j.jtcme.2017.07.003
   PubMedGoogle Scholar
• Fan Q, Li J, Xu C, Wu S. Effects of Rehmannia glutinosa polysaccharides on the proliferation and apoptosis of K562 cells. Pak J Pharm Sci. 2020;33(4):1555–60.
   PubMed Web of Science ®Google Scholar
• Harsha M, Mohan Kumar KP, Kagathur S, Amberkar VS. Effect of Ocimum sanctum extract on leukemic cell lines: A preliminary in-vitro study. J Oral Maxillofac Pathol. 2020;24(1):93–8. doi:10.4103/jomfp.JOMFP_181_19
   PubMedGoogle Scholar
• Rodrigues ACBdC, Oliveira FPd, Dias RB, Sales CBS, Rocha CAG, Soares MBP, Costa EV, Silva FMAd, Rocha WC, Koolen HHF, et al. In vitro and in vivo anti-leukemia activity of the stem bark of Salacia impressifolia (Miers) A. C. Smith (Celastraceae). J Ethnopharmacol. 2019;231:516–24. doi:10.1016/j.jep.2018.11.008
   PubMed Web of Science ®Google Scholar
• Chen C, Li P, Li Y, Yao G, Xu JH. Antitumor effects and mechanisms of Ganoderma extracts and spores oil. Oncol Lett. 2016;12(5):3571–8. doi:10.3892/ol.2016.5059
   PubMed Web of Science ®Google Scholar
• Chi HT, Thuong NTL, Ly BTK. Sphagneticola Trilobata (L.) Pruski (Asteraceae) methanol extract ınduces apoptosis in leukemia cells through suppression of BCR/ABL. Plants (Basel). 2021;10(5):980. doi:10.3390/plants10050
   PubMedGoogle Scholar
• Ayesh BM, Abed AA, Faris DM. In vitro inhibition of human leukemia THP-1 cells by Origanum syriacum L. and Thymus vulgaris L. extracts. BMC Res Notes. 2014;7:612. doi:10.1186/1756-0500-7-612
   PubMedGoogle Scholar
• Zhamanbayeva GT, Aralbayeva AN, Murzakhmetova MK, Tuleukhanov ST, Danilenko M. Cooperative antiproliferative and differentiation-enhancing activity of medicinal plant extracts in acute myeloid leukemia cells. Biomed Pharmacother. 2016;82:80–9. doi:10.1016/j.biopha.2016.04.062
   PubMed Web of Science ®Google Scholar
• Abdel-Massih RM, Fares R, Bazzi S, El-Chami N, Baydoun E. The apoptotic and anti-proliferative activity of Origanum majorana extracts on human leukemic cell line. Leuk Res. 2010;34(8):1052–6. doi:10.1016/j.leukres.2009.09.018
   PubMed Web of Science ®Google Scholar
• Abotaleb M, Samuel S, Varghese E, Varghese S, Kubatka P, Liskova A, Büsselberg D. Flavonoids in cancer and apoptosis. Cancers (Basel). 2018;11(1):28. doi:10.3390/cancers11010028
   PubMed Web of Science ®Google Scholar
• El-Baba C, Baassiri A, Kiriako G, Dia B, Fadlallah S, Moodad S, Darwiche N. Terpenoids’ anti-cancer effects: focus on autophagy. Apoptosis. 2021;26(9–10):491–511. doi:10.1007/s10495-021-01684-y
   PubMed Web of Science ®Google Scholar
• Cai Y, Zhang J, Chen NG, Shi Z, Qiu J, He C, Chen M. Recent advances in anticancer activities and drug delivery systems of tannins. Med Res Rev. 2017;37(4):665–701. doi:10.1002/med.21422
   PubMed Web of Science ®Google Scholar
• Lewandowska U, Gorlach S, Owczarek K, Hrabec E, Szewczyk K. Synergistic interactions between anticancer chemotherapeutics and phenolic compounds and anticancer synergy between polyphenols. Postepy Hig Med Dosw (Online). 2014;68:528–40. doi:10.5604/17322693.1102278
   PubMedGoogle Scholar
• Kamel KM, Khalil IA, Rateb ME, Elgendy H, Elhawary S. Chitosan-coated cinnamon/oregano-loaded solid lipid nanoparticles to augment 5-fluorouracil cytotoxicity for colorectal cancer: Extract standardization, nanoparticle optimization, and cytotoxicity evaluation. J Agric Food Chem. 2017;65(36):7966–81. doi:10.1021/acs.jafc.7b03093
   PubMed Web of Science ®Google Scholar
• Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci. 2015;143(1):147–55. doi:10.1093/toxsci/kfu215
   PubMed Web of Science ®Google Scholar
• Stanchina M, McKinnell Z, Park JH, Stein EM, Cai SF, Taylor J. BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon. Leuk Res Rep. 2020;14:100211. doi:10.1016/j.lrr.2020.100211
   PubMedGoogle Scholar
• Soliman AM, Desouky S, Marzouk M, Sayed AA. Origanum majorana attenuates nephrotoxicity of cisplatin anticancer drug through ameliorating oxidative stress. Nutrients. 2016;8(5):264. doi:10.3390/nu8050
   Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441–53. doi:10.1038/nrc2147
   PubMed Web of Science ®Google Scholar
• O’Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011;17(2):212–21. doi:10.1158/1078-0432.CCR-09-3314
   PubMed Web of Science ®Google Scholar
• Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010;3:8. doi:10.1186/1756-8722-3-8
   PubMed Web of Science ®Google Scholar
• Danisz K, Blasiak J. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Acta Biochim Pol. 2013;60(4):503–14.
   PubMed Web of Science ®Google Scholar
• Melo JV, Deininger MW. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18(3):545–68. doi:10.1016/j.hoc.2004.03.008
   PubMed Web of Science ®Google Scholar
• Ilaria RL, Van Etten RA.Jr., Van Etten RA: P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271(49):31704–10. doi:10.1074/jbc.271.49.31704
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355–68. doi:10.1016/j.ccr.2005.10.015
   PubMed Web of Science ®Google Scholar
• Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7(2):105–17. doi:10.1038/nri2024
   PubMed Web of Science ®Google Scholar
• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010–22. doi:10.1182/blood-2003-12-4111
   PubMed Web of Science ®Google Scholar
• Hocevar BA, Howe PH. Mechanisms of TGF-beta-induced cell cycle arrest. Miner Electrolyte Metab. 1998;24(2–3):131–5. doi:10.1159/000057360
   PubMedGoogle Scholar
• Goodarzi AA, Block WD, Lees-Miller SP. The role of ATM and ATR in DNA damage-induced cell cycle control. Prog Cell Cycle Res. 2003;5:393–411.
   PubMedGoogle Scholar
• Wlodarchak N, Xing Y. PP2A as a master regulator of the cell cycle. Crit Rev Biochem Mol Biol. 2016;51(3):162–84. doi:10.3109/10409238.2016.1143913
   PubMed Web of Science ®Google Scholar
• Li Y, Shi F, Hu J, Xie L, Zhao L, Tang M, Luo X, Ye M, Zheng H, Zhou M, et al. Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. NPJ Precis Oncol. 2021;5(1):14. doi:10.1038/s41698-021-00153-8
   PubMed Web of Science ®Google Scholar
• Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187–90. doi:10.1016/s0968-0004(00)89005-2
   PubMed Web of Science ®Google Scholar
• Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59(8):1317–26. doi:10.1007/s00018-002-8510-y
   PubMed Web of Science ®Google Scholar